Advertisement

Topics

ADA 2017: Outlook For New Longer Acting Insulins Amid US Pricing Sensitivity

07:52 EDT 20 Jun 2017 | SCRIP

The high cost of basal insulins in the US has drawn a fair amount of scrutiny recently, placing increased pressure...

      

Related Stories

 

Original Article: ADA 2017: Outlook For New Longer Acting Insulins Amid US Pricing Sensitivity

NEXT ARTICLE

More From BioPortfolio on "ADA 2017: Outlook For New Longer Acting Insulins Amid US Pricing Sensitivity"

Advertisement
Quick Search
Advertisement
Advertisement